Intervencionista
Un ensayo clínico en el que se usa un nuevo medicamento o dispositivo para medir un resultado específico.
Visionary
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy (IgAN)
This phase 3 trial will assess the efficacy and safety of sibeprenlimab administered SC once every 4 weeks as an add-on to standard of care (SOC) treatment (eg, angiotensin-converting enzyme inhibitors [ACEIs] and/or angiotensin receptor blockers [ARBs]). Furthermore, subjects who are on a stable dose of sodium-glucose cotransporter-2 inhibitors (SGLT2i) therapy for IgAN, in addition to ACEIs and/or ARBs, may participate in the trial if treatment was initiated at least 3 months prior to
screening.
Médico del ensayo/Coordinador del estudio
Jeovani Orellana
Correo electrónicoNombre del sitio
Amicis Research Center
9241 Reseda Blvd Suite B Northridge, CA 91324
Intervencionista
Un ensayo clínico en el que se usa un nuevo medicamento o dispositivo para medir un resultado específico.
Visionary
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy (IgAN)
This phase 3 trial will assess the efficacy and safety of sibeprenlimab administered SC once every 4 weeks as an add-on to standard of care (SOC) treatment (eg, angiotensin-converting enzyme inhibitors [ACEIs] and/or angiotensin receptor blockers [ARBs]). Furthermore, subjects who are on a stable dose of sodium-glucose cotransporter-2 inhibitors (SGLT2i) therapy for IgAN, in addition to ACEIs and/or ARBs, may participate in the trial if treatment was initiated at least 3 months prior to
screening.
Criterios de elegibilidad
Población de pacientes
Immunoglobulin A Nephropathy
Edad
18 — 26+
¿Pueden los pacientes con trasplante de riñón calificar para este ensayo?
No
¿Los pacientes que se encuentran actualmente en diálisis pueden calificar para este ensayo?
No
TFGe
15 a 29 — > 60
UPCR
1,1 a 2,0 — 3,0 o más
¿Qué tratamientos pueden haber tomado los pacientes para calificar para este ensayo?
Inhibidores ACE/ARB, Prednisona (Esteroides), Otro
¿Qué tipo de pacientes de las categorías siguientes pueden participar?
Resistente al tratamiento
Sobre el medicamento o la intervención
Qué implica para el paciente
Subjects will be evaluated throughout the trial for safety, efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and immunogenicity assessments. The total trial duration for each subject will be approximately 121 weeks (assuming up to60 days [approximately 9 weeks] for screening, 26 doses administered once every4 weeks from Day 1 to Week 100, a follow-up visit in Week 104, and ending with an end-of-trial visit in Week 112).
Nombre del patrocinador
Otsuka Pharmaceutical Development & Commercialization, Inc.
Fecha estimada de finalización
2026
Sobre el estudio
Nombre del fármaco del estudio
Sibeprenlimab
Objetivo del estudio
Sibeprenlimab is being developed for the treatment of immunoglobin A nephropathy (IgAN), a chronic disease affecting the kidneys which is characterized clinically by proteinuria, hematuria, and progressive decline of glomerular filtration rate and histologically by deposition of Immunoglobulin A (IgA) in the kidney. This phase 3 trial will assess the efficacy and safety of sibeprenlimab administered SC once every 4 weeks as an add-on to standard of care (SOC) treatment.
Sobre el medicamento o la intervención
Sibeprenlimab (VIS649) is a humanized IgG2 monocolonal antibody directed against the functionally conserved receptor binding domain of APRIL, blocking binding to its receptors, TACI, and BCMA.